Defibrotide is a mixture of porcine oligodeoxyribonucleotides that reduces procoagulant activity and increases fibrinolytic activity as well as being protective to activated endothelial cells. It is in development for cerebral malaria and multiple myeloma. There is evidence that it may decrease graft versus host disease and it can reduce childhood hepatic veno-occlusive disease in haemopoietic stem cell transplantation patients.
- ↑ Guglielmelli T, Bringhen S, Palumbo A. Update on the use of defibrotide. Expert opinion on biological therapy. 2012 Mar; 12(3):353-61.(Link to article – subscription may be required.)
- ↑ Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, Boelens JJ, Hewitt A, Schrum J, Schulz AS, Müller I, Stein J, Wynn R, Greil J, Sykora KW, Matthes-Martin S, Führer M, O'Meara A, Toporski J, Sedlacek P, Schlegel PG, Ehlert K, Fasth A, Winiarski J, Arvidson J, Mauz-Körholz C, Ozsahin H, Schrauder A, Bader P, Massaro J, D'Agostino R, Hoyle M, Iacobelli M, Debatin KM, Peters C, Dini G. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012 Feb 22.(Epub ahead of print) (Link to article – subscription may be required.)
- ↑ Zhang L, Wang Y, Huang H. Defibrotide for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review. Clinical transplantation. 2012 Mar 20.(Epub ahead of print) (Link to article – subscription may be required.)